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Abstract
Background: Cervical cancer is a major public health problem in Latin America and the Caribbean (LA&C), showing some of
the highest incidence and mortality rates worldwide. Information on HPV type distribution in high-grade cervical lesions
(HSIL) and invasive cervical cancer (ICC) is crucial to predict the future impact of HPV16/18 vaccines and screening
programmes, and to establish an appropriate post-vaccinal virologic surveillance. The aim was to assess the prevalence of
HPV types in HSIL and ICC in studies in LA&C.
Methods and Findings: We performed a systematic review, following the MOOSE guidelines for systematic reviews of
observational studies, and the PRISMA statement for reporting systematic reviews and meta-analyses. Inclusion criteria were
at least ten cases of HSIL/ICC, and HPV-type elicitation. The search, without language restrictions, was performed in
MEDLINE, Cochrane Library, EMBASE, LILACS from inception date to December 2009, proceedings, reference lists and
consulting experts. A meta-analysis was performed using arc-sine transformations to stabilize the variance of simple
proportions. Seventy-nine studies from 18 countries were identified, including 2446 cases of HSIL and 5540 of ICC. Overall,
46.5% of HSIL cases harbored HPV 16 and 8.9% HPV18; in ICC, 53.2% of cases harbored HPV 16 and13.2% HPV 18. The next
five most common types, in decreasing frequency, were HPV 31, 58, 33, 45, and 52. Study’s limitations comprise the cross-
sectional design of most included studies and their inherent risk of bias, the lack of representativeness, and variations in the
HPV type-specific sensitivity of different PCR protocols.
Conclusions: This study is the broadest summary of HPV type distribution in HSIL and ICC in LA&C to date. These data are
essential for local decision makers regarding HPV screening and vaccination policies. Continued HPV surveillance would be
useful, to assess the potential for changing type-specific HPV prevalence in the post-vaccination era in Latin America.
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Introduction
Human papillomavirus infection (HPV) is one of the most
common sexually transmitted diseases worldwide [1]. Infection by
certain types of HPV is recognized as a causal and necessary factor
in the development of cervical cancer [2]. Cervical cancer
represents the second-most common malignancy in women
around the world and contributes to 9.8% of all female cancers
[3]. Cervical cancer accounts for 10% of all female cancers,
making it the second leading cause of cancer death in women.
Worldwide, there were approximately 500,000 incident cases and
275,000 deaths due to cancer of the cervix in 2002. Latin America
and the Caribbean accounted for 15% and 11%, respectively, of
this burden [4]. The age-standardized cervical cancer incidence
rate is 30.6 per 100,000 persons in Central America, and 28.6 per
100,000 persons in South America [5].
It is now recognized that virtually all cervical cancers (both the
squamous and adenocarcinoma histological types) and their
precursor lesions are causally related to cervical infections through
at least 14 oncogenic HPV genotypes (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66 and 68) [6,7]. However, only a minority of
pre-neoplastic lesions progress to cancer; the HPV type is a robust
risk factor for differential progression [8]. Since cervical cancer
affects relatively young women, it represents the single biggest
cause of years of life lost (YLL) from cancer in the developing
world, contributing more to this burden of disease measure than
do tuberculosis, maternal conditions or acquired immunodeficien-
cy syndrome (AIDS) [9]. In developed countries, Papanicolaou
(PAP) smear test screening has decreased the incidence of cervical
cancer by about 70% in recent decades; however, it still represents
a major public health issue in LA&C because of the failure of
prevention programs [4]. Previous meta-analyses have reported
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in HSIL or cervical cancer worldwide; however, this data is
variable and incomplete for LA&C populations [10–14]. Regional
data on type-distribution is essential for estimating the impact of
vaccines on cervical cancer and for the development of screening
programs. The aim of the present study is to assess exhaustively
the HPV type distribution in HSIL and ICC in studies in LA&C
region.
Materials and Methods
We performed a systematic review, following the Meta-analysis
Of Observational Studies in Epidemiology (MOOSE) guidelines
[15] for systematic reviews of observational studies, and the
Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement for reporting systematic reviews
and meta-analyses [16,17], which replaced the Quality Of
Reporting Of Meta-analysis (QUOROM) statement [18].
Search methodology
A search, without language restrictions, was performed on the
main international and regional literature databases MEDLINE;
EMBASE; CINAHL; NHS R&D Health Technology Assessment
Program; ClinicalTrials.gov; LILACS; Cab International Global
Health; Pascal Biomed; generic and academic internet search and
meta-search engines; and the specialized register of the Cochrane
Gynecological Cancer Group from its inception date to December
2009. Databases containing regional proceedings or congress’s
annals, doctoral theses and experts were also consulted.
The Medline, LILACS, and EMBASE search strategy is
available at the Appendix S1. An exhaustive strategy module
was developed to localize studies from LA&C. According to
pre-specified criteria, pairs of authors independently examined the
title, abstract, and descriptors of the articles in order to identify
potentially relevant studies for full review. The reference lists of the
articles finally included were hand-searched for additional
information. If data or data subsets of the same population were
published in more than one article, only the publication with the
largest sample size was selected, after consulting the principal
investigator. Discrepancies were resolved by consensus or, finally,
by a third author. The full texts of relevant articles retrieved were
examined using a pre-designed form.
Types of studies and participants
Any descriptive epidemiological study with individual-level data
was considered. Participant subjects were women from LA&C
countries, in studies of cervical cancer/HSIL associated with
HPV. The inclusion criteria were a) to inform at least ten cases of
HSIL or ICC, b) confirmed by biopsy, and c) HPV-type
elicitation. We excluded those papers that undoubtedly failed to
meet the aforementioned inclusion criteria. Studies using both
polymerase chain reaction (PCR)-amplified and non-amplified
genotyping methods were included. There were no restrictions on
PCR primers’ utilization. HPV DNA tissue sources included fixed
or fresh biopsies and/or exfoliated cells. Outcome measures
included global and type-specific HPV prevalence. Two attempts
of email contact with the author were made in order to recover
missing data.
Methodological quality assessment
Two reviewers assessed the methodological quality of studies
independently. Discrepancies were solved by consensus of the
whole team. Observational studies or control arms of randomized
controlled trials were assessed by a checklist of essential items
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0025493.g001
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Observational studies in Epidemiology) statement, two methodo-
logical papers [20,21] and the general guidelines of MOOSE [15].
(See Appendix S2)
Pairs of reviewers independently abstracted the following key
information: country where the samples were drawn, setting,
population, sample size, study design, age, study year, distribution
of cases by histological type, type of cervical specimen and PCR
primers, type-specific and overall prevalence of HPV infection,
reported duration of HPV infection, and quality score. Data on
HPV-specific prevalence was extracted independently for squa-
mous cell carcinoma (SCC) and for adeno- and adenosquamous
carcinoma. Each study, or regional components of a study, was
classified by the following criteria: 1) geographical region (Central
America/Mexico/The Caribbean or South America) 2) income
level as defined by the Gross Nation Income (GNI) World Bank
Classification (lower-middle income, upper-middle income, high
income), 3) tissue source (exfoliated cells, fixed biopsies, fresh
biopsies, combined), and 4) genotyping method (Southern blot,
Dot blot, FISH and In Situ Hybridization), PCR 1 (PCR MY09/
11 or Consensus primers), PCR 2 (PCR SPF, GP5/6, E6, E7 and
others) and PCR 3 (PCR MY and GP performed together).
Statistical analysis
HPV prevalence data was expressed as a percentage of all cases
tested for HPV. Multiple infections were separated into constituent
types, thus type-specific prevalence represents both single and
multiple infections. For HPV type-specific prevalence, only studies
testing for a particular HPV type contribute to the analysis for that
type, and therefore sample size varied between the type-specific
analyses. In order to perform a meta-analysis with prevalence
data, we first transformed proportions into a quantity (the
Freeman-Tukey variant of the arcsine square root transformed
proportion) [22]. The pooled proportion was calculated as the
back-transformation of the weighted mean of the transformed
proportions, using inverse arcsine variance weights for the fixed
effects model. The arcsine transformations were necessary to
stabilize the variance of simple proportions.
One must consider that each HPV type proportion is a pooled
estimate of only those studies reporting the particular HPV type.
Hence, each proportion has its own denominator and must be
considered regardless of the other types. Thus, cumulative point
estimates do not sum to 100%. DerSimonian-Laird weights for the
random effects model [23] were applied where heterogeneity
between studies was found. The I
2 statistic quantifies the
heterogeneity between studies. This statistic describes the
percentage of the variability in effect estimates that is due to
heterogeneity rather than sampling error (chance). [24] We used
Statsdirect and STATA 8.0.
We hypothesized the following possible sources of heterogene-
ity: age, risk factors of HPV and/or HSIL/cervical cancer,
country, geographical region, income level by the Gross National
Income (GNI) World Bank Classification, type of cervical lesion,
type of tissue source and type of genotyping method used. With
the available data we could perform pre-designed subgroup
analyses considering the country where the study was carried out,
the geographical region, the income level of the country according
the Gross National Income (GNI) World Bank Classification, the
type of genotyping method and the tissue source. Additionally, we
applied a meta-regression analysis in order to further study the
Table 1. HSIL and CANCER prevalence by HPV type.
HPV TYPE HSIL CANCER CANCER:HSIL
N6 of patients Prevalence % N6 of patients Prevalence % Prevalence
(N6 of Studies) (95% CI) (N6 of Studies) (95% CI) ratio
Global 2446 (52) 5540 (62)
Any 1749 (36) 82.5 (77.3–87.1) 3435 (43) 89.0 (84.3–92.9) 1.08
Type 6 1415 (29) 4.2 (2.2–6.7) 2274 (32) 1.7 (0.9–2.8) 0.4
Type 11 1414 (29) 2.4 (1.3–3.8) 2274 (32) 1.3 (0.5–2.5) 0.54
Type 16 2327 (49) 46.5 (41.3–51.7) 5463 (60) 53.2 (49.1–57.2) 1.14
Type 18 2194 (45) 8.9 (6.3–11.8) 4962 (56) 13.2 (11.0–15.6) 1.48
Type 31 1785 (36) 8.0 (6.0–10.4) 3903 (45) 7.5 (5.5–9.8) 0.94
Type 33 1722 (35) 6.5 (4.7–8.5) 3821 (42) 4.3 (3.2–5.5) 0.66
Type 35 1228 (24) 3.0 (1.9–4.4) 2332 (31) 2.0 (1.3–2.7) 0.67
Type 39 885 (20) 2.4 (1.5–3.5) 1977 (27) 1.8 (1.3–2.4) 0.75
Type 45 1077 (24) 3.9 (2.8–5.2) 3389 (37) 4.6 (3.5–5.7) 1.18
Type 51 1013 (21) 3.7 (2.1–5.7) 2131 (30) 2.1 (1.1–3.3) 0.57
Type 52 1152 (25) 4.9 (2.9–7.4) 2544 (34) 3.2 (2.1–4.4) 0.65
Type 56 892 (19) 2.4 (1.5–3.4) 2155 (28) 1.2 (0.8–1.7) 0.5
Type 58 1197 (26) 8.7 (6.0–11.9) 2564 (34) 3.0 (2.1–4.1) 0.34
Type 59 954 (21) 1.9 (1.2–2.9) 2199 (30) 1.6 (1.1–2.2) 0.84
Type 66 926 (20) 1.8 (1.1–2.8) 2095 (28) 1.1 (0.7–1.6) 0.61
Type 68 619 (14) 1.3 (0.6–2.3) 1864 (23) 0.5 (0.3–0.9) 0.38
Other* 1479 (32) 11.6 (7.6–16.2) 3177 (34) 7.5 (5.0–10.4) 0.65
Multiple 1431 (29) 16.8 (12.9–21.2) 2090 (27) 12.6 (8.7–17.2) 0.75
doi:10.1371/journal.pone.0025493.t001
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prevalence. Publication bias was unlikely as assessed by funnel plots
although this type of bias is unlikely to occur in prevalence studies
(data not shown). No ethical approval was required for this study.
Results
The present Systematic Review and Meta-analysis met the
PRISMA statement requirements (See Checklist S1 and
Diagram S1).
Overall, 1452 citations were retrieved from the search strategy.
After the assessment (Figure 1), 79 studies from 18 countries,
totaling 7986 women, met the inclusion criteria [25–100]. Study
characteristics are presented in Appendix S3. Nine countries
were from Central America/Mexico/The Caribbean (31.8% of
the women) and nine countries from South America (68.2%). One
country, was a high-income nation (0.3% of women), six countries
were middle-income (72.3%), and eleven countries were low-
income (27.4%).
We considered 114 sub-studies for the analysis, including
seven country-level sub-studies from Bosch 1995 [29] and
discriminated sub-studies by cervical lesion (52 sub-studies
evaluated patients with HSIL and 62 evaluated patients with
cervical cancer). Thirteen studies had a moderate risk of bias
[29,41,44,68,70,73,82,92,101–105] and the rest carried a high risk
of bias. HPV DNA was retrieved from fixed biopsies in 34.2%,
from exfoliated cells in 34.2%, from fresh biopsies in 19.7%, and
from exfoliated cells and fresh biopsies in 11.8% of the studies.
Most of the authors used PCR MY09/11 or non-specified
consensus primers (n=30), while the rest used membrane or in-
situ hybridization (n=9), PCR GP5/6 or SPF or others (i.e. E6
and E7) (n=30), or PCR using MY and GP together (n=8)
(Appendix S3).
HSIL/ICC cases came mainly from Brazil (23.7%), Argentina
(19.0%), and Mexico (17.9%). The HSIL and ICC prevalence,
and ICC:HSIL prevalence ratio by type are presented in Table 1.
HPV16 and HPV18, were the first- and second-most common
types, respectively for both HSIL and ICC. HPV18, 45 and 16
had the highest ICC:HSIL prevalence ratio (1.48, 1.18, and 1.14
respectively). Conversely, HPV11, 56, 6, 68 and 58, were each 2 to
3-fold more prevalent in HSIL than in ICC.
The comparison of HPV type-specific prevalence cancer and
HSIL cases is illustrated by Figure 2.
High grade intraepithelial lesions (HSIL)
In the 52 sub-studies included in the HSIL systematic review, 16
were performed in Mexico or Central America and 36 in South
America. Overall, a total of 2446 patients’ samples were analyzed
with a median of 47.5 specimens in each sub-study (range 6 to
130). Most data came from cross-sectional studies (n=39) while
seven came from case-control studies, four from cohort studies/
prospective follow up, one from a nested case-control study, one
from a before-after study and one from a randomized controlled
trial. Mean age of women was 40.467.6 years old.
Figure 2. HPV type-specific prevalence in Cancer and HSIL, with 95% CIs.
doi:10.1371/journal.pone.0025493.g002
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doi:10.1371/journal.pone.0025493.g003
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doi:10.1371/journal.pone.0025493.g004
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(95% CI 77.3–87.1%; I
2=86.4%) of samples, while prevalence of
HPV16 was 46.5% (95% CI 41.3–51.7%; I
2=84.6%) and
prevalence of HPV18 was 8.9% (95% CI 6.3–11.8%;
I
2=80.0%) (Table 1, Figure 3, 4). Multiple HPV infections
were seen in 16.8% (95% CI 12.8–21.4; I
2=77.0%) of the
analyzed samples.
Table 2 presents the HPV16/18 prevalence in ICC and HSIL
by country, region, and Gross National Income (GNI) from the
World Bank’s classification. In Argentina (12 studies) the pooled
prevalence of HPV16 in HSIL samples was 48.5% (95% CI 36.7–
60.3%; I
2=85.8%). In Brazil (13 studies) the pooled prevalence of
HPV16 in HSIL samples was 52.7% (95% CI 45.6–59.6%; I
2
56.8%). In Mexico (9 studies), the pooled prevalence of HPV16 in
HSIL samples was 48.5% (95% CI 35.5–61.6%; I
2 86.1%).
We found a pooled prevalence of HPV18 in HSIL of 16.9%
(95% CI 9.8–25.4%; I
2 81.2%) in Argentina, 9.0% (95% CI 5.0–
14.1%; I
2=66.0%) in Brazil, and 6% (95% CI 3.1–9.7%;
I
2=50.6%) in Mexico. HPV prevalence according to subgroups
of geographic region and by GNI World Bank Classification are
shown in Table 2. The subgroup analyses by primers used and by
tissue source are shown in Table 3.
Cervical cancer
In the 62 sub-studies included in the ICC systematic review, a
total of 5540 patients’ samples were analyzed with a median of 56
specimens in each study (range 14 to 750). Most data came from
cross-sectional studies (n=52) while 10 came from case-control
studies, and one nested case-control study. Mean age of women
was 41.167.0 years old.
Any HPV in cervical cancer was found in a pooled proportion
of 89.0% (CI 84.3–92.9%; I
2=94.0%) of the samples, while the
prevalence of HPV16 was 53.2% (CI 49.1–57.2%; I
2=88.5%)
and the prevalence of HPV18 was 13.2% (CI 11.0–15.6%;
I
2=81.1%) (Table 1, Figure 5, 6). Multiple HPV infections
were seen in 12.6% (CI 8.7–17.2%; I
2=87.8%) of the samples.
Table 2. HPV16/18 prevalence in ICC and HSIL: subgroup analysis by country, region, and GNI World Bank classification.
Subgroups HSIL CERVICAL CANCER
HPV TYPE: 16 HPV TYPE: 18 HPV TYPE: 16 HPV TYPE: 18
Np a t i e n t s
(studies)
Prevalence
(95% CI)
Np a t i e n t s
(studies)
Prevalence
(95% CI)
Np a t i e n t s
(studies)
Prevalence
(95% CI)
Np a t i e n t s
(studies)
Prevalence
(95% CI)
GLOBAL 2327 (49) 46.5 (41.3–51.7) 2194 (45) 8.9 (6.3–11.8) 5463 (60) 53.2 (49.1–57.2) 4962 (56) 13.2 (11–15.6)
By country
Argentina 502 (12) 48.5 (36.7–60.3) 490 (11) 16.9 (9.8–25.4) 1013 (10) 59.5 (51.3–67.5) 1013 (10) 17.6 (12–24.1)
Barbados - - - - 21 (1) 71.4 (47.8–88.7) - -
Belize 15 (1) 46.7 (21.3–73.4) 15 (1) 0 (0–0) - - - -
Bolivia - - - - 49 (1) 34.7 (21.7–49.6) 49 (1) 4.1 (0.5–14)
Brazil 466 (13) 52.7 (45.6–59.6) 466 (13) 9 (5–14.1) 1269 (13) 53.2 (42.9–63.3) 1269 (13) 15.8 (8.9–24.2)
Chile 95 (3) 18.5 (5.8–36.3) 73 (2) 5.9 (0.2–26.2) 420 (4) 51.8 (29.7–73.5) 420 (4) 9.5 (4.2–16.7)
Colombia 241 (3) 56.7 (31.2–80.4) 209 (2) 4.9 (1.7–29.5) 450 (4) 46.7 (35.9–57.7) 450 (4) 7.5 (3.7–12.6)
Costa Rica 130 (1) 43.1 (34.4–52) 130 (1) 7.4 (2.8–15.4) 35 (1) 45.7 (28.8–63.4) 35 (1) 17.1 (6.6–33.6)
Cuba 45 (1) 31.1 (18.2–46.6) 45 (1) 6.3 (0.8–20.8) 45 (1) 57.8 (42.2–72.3) 45 (1) 6.7 (1.4–18.3)
Ecuador 32 (1) 81.3 (63.6–92.8) 32 (1) 4.5 (0.9–12.7) 47 (1) 80.9 (66.7–90.9) 47 (1) 4.3 (0.5–14.5)
Honduras 81 (1) 35.8 (25.4–47.2) 81 (1) 6.9 (3.2–12.7) 104 (1) 43.3 (33.6–53.3) 104 (1) 10.6 (5.4–18.1)
Jamaica 66 (1) 24.2 (14.5–36.4) 66 (1) 6.7 (1.4–18.3) - - - -
Mexico 405 (9) 48.5 (35.5–61.6) 405 (9) 6 (3.1–9.7) 1021 (14) 54.9 (47.6–61.9) 840 (13) 12.8 (9.7–16.2)
Nicaragua 175 (2) 28.8 (22.4–35.7) 108 (1) 6.7 (1.4–18.3) 136 (2) 38.1 (17–61.9) 19 (1) 5.3 (0.1–26)
Panama - - - - 255 (2) 41.6 (31.3–52.2) 73 (1) 15.1 (7.8–25.4)
Paraguay 74 (1) 41.9 (30.5–53.9) 74 (1) 1.4 (0–7.3) 154 (2) 61.3 (33.9–85.2) 154 (2) 7.2 (1.8–15.7)
Peru - - - - 198 (1) 55.6 (48.3–62.6) 198 (1) 12.6 (8.3–18.1)
Suriname - - - - 246 (2) 42.2 (29.4–55.7) 246 (2) 16.3 (12–21.2)
By geographic region
Central America and Mexico 917 (16) 41.7 (33.8–49.8) 850 (15) 6.3 (4.6–8.3) 1617 (22) 51.7 (45.6–57.8) 1116 (18) 12.5 (10.1–
15.1)
South America 1410 (33) 48.9 (42.2–55.5) 1344 (30) 10.5 (6.6–15.1) 3846 (38) 54.0 (48.6–59.2) 3846 (38) 13.3 (10.4–
16.5)
By GNI World Bank
classification
Lower middle income 714 (10) 43.6 (32.8–54.8) 615 (8) 5.5 (2.3–10.1) 1429 (15) 49.4 (42.6–56.2) 1312 (14) 9.5 (7.2–12)
Upper middle income 1613 (39) 47.3 (41.5–53.2) 1579 (37) 9.8 (6.8–13.2) 4013 (44) 54.1 (49.2–58.9) 3650 (42) 14.8 (11.9–18)
High income - - - - 21 (1) 71.4 (47.8–88.7) - -
doi:10.1371/journal.pone.0025493.t002
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by country, region, and GNI World Bank Classification. In
Argentina (10 studies), the pooled prevalence of HPV16 in cancer
samples was 59.5% (95% CI 51.3–67.5%; I
2=68.2%), in Brazil
(13 studies) 53.2% (95% CI 42.9–63.3%; I
2=92.5%), and in
Mexico (14 studies) 54.9% (95% CI 47.6–61.9%; I
2=80.3%).
When we analyzed the prevalence of HPV18 in ICC samples,
we found a pooled prevalence of 17.6% (95% CI 12–24.1%;
I
2=65.7%) in Argentina, 15.8% (95% CI 8.9–24.2%; I
2=92.8%)
in Brazil, and 12.8% (95% CI 9.7–16.2%; I
2=47.6%) in Mexico.
HPV prevalence by the geographic region and by GNI World
Bank Classification are shown in Table 2. The analyses by
primers used and by tissue source are shown in Table 3. The
distributions of HPV 16/18 in HSIL and ICC in LA&C according
to quartiles of prevalence are shown in maps in Figures 7 and 8.
We also applied a meta-regression analysis adjusting by GNI
World Bank Classification, Geographic region, genotyping
method and HPV tissue source to obtain adjusted estimates.
There were no statistically significant differences for HPV16 in
cancer and in HSIL. For HPV18, the statistically significant
difference were seen for HSIL when the tissue source was fixed
biopsies (compared to exfoliated cells) and when MY and GP
performed together were used compared to Hybridization
techniques and for cancer when the tissue source were Polymerase
Chain Reaction SPF, GP5/6, E6, E7 and others compared to
Hybridization techniques. However the adjusted prevalence, by
the means of each variable and considering the SE of the meta-
analysis, remained stable: HPV16 in HSIL women 45.7% (CI
95% 42.9–48.5%) HPV18 in HSIL 8.7% (7.2–10.3%); HPV16 in
ICC 55.3% (52.5–58.1%); and HPV18 in ICC 13.4 (11.5–15.3).
Funnel plots showed no evidence of publication bias (data not
shown).
Discussion
Data on the geographic distribution of HPV type in HSIL and
ICC are crucial for estimating the impact of HPV vaccines on
cervical cancer and cervical screening programs. [106,107]
Epidemiological studies employing a variety of HPV typing
protocols have been aggregated in some meta-analyses. However,
the number of samples from LA&C considered in these studies was
relatively low.
This review brings representative estimations of HPV type
distribution from the LA&C region. Since multiple HPV
genotyping techniques have been included, varying sensitivities
of the techniques considered might impact the HPV type-specific
prevalence reported [108]. Currently, identification of specific
HPV types in biological specimens is preferentially done by PCR-
based methods due to its higher sensitivity; in this study, however,
hybridization techniques without PCR amplification (membrane
and in situ hybridization) were also included in order to
incorporate the largest number of HSIL and ICC cases, and to
increase the representativeness of the data. Nevertheless, only 6%
of studies -the oldest ones- used non-PCR-based techniques.
In 2003, Smith et al. [14] updated a meta-analysis of over
10,000 cases published [10,11]. It retrieved 1,427 cancer cases and
833 HSIL cases from 13 countries in the LA&C region; the
prevalence of HPV 16/18 in cervical cancer for South/Central
America was 65%. Mun ˜oz et al., in 2004, included 1,084 cervical
cancer cases from Central/South America and found an HPV16/
18 prevalence of 69%. [13]. Later, Li et al have published a
worldwide meta-analysis of HPV type-specific including a total of
30,848 cervical cancers. It included 3,010 cancer cases from 15
countries of LA&C; in this region for 1990–2010, HPV16 and
HPV18 were the first and second most common types, respectively
(54% and 15% respectively); being the third to eighth most
common types HPVs 31, 45, 33, 58, 52 and 35. [12]. The present
systematic tripled the number HSIL cases included in the previous
reports of Clifford et al. [10,11] and Smith et al. [14]. Overall,
55% of HSIL cases harbored HPV 16/18, confirming that HPV
type distribution in HSIL does not entirely match that of ICC.
HPV types 16, 18 and 45 are less common in HSIL than in ICC,
whereas other HPV types are more frequent (particularly, HPV58,
the third-most prevalent type in HSIL). These differences
emphasize the importance of HPV type in the risk of progression
to cancer, even from HSIL. The proportions of HSIL cases
Table 3. HPV16/18 prevalence in ICC and HSIL: subgroup analysis by genotyping method and tissue source.
Subgroups HSIL CERVICAL CANCER
HPV TYPE: 16 HPV TYPE: 18 HPV TYPE: 16 HPV TYPE: 18
N patients
(studies)
Prevalence
(95% CI)
N patients
(studies)
Prevalence
(95% CI)
N patients
(studies)
Prevalence
(95% CI)
N patients
(studies)
Prevalence
(95% CI)
By Genotyping Method
Hybridization techniques* 494 (8) 37.1 (31.6–42.7) 427 (7) 8.2 (1.6–19.3) 998 (15) 47.7 (39.1–56.4) 816 (14) 12.0 (9–15.4)
PCR 1** 948 (23) 48.2 (39.7–56.7) 882 (20) 7.6 (6–9.4) 1355 (18) 58.5 (51.2–65.7) 1174 (17) 11.3 (7.5–15.7)
PCR 2
{ 560 (12) 42.9 (33.5–52.7) 560 (12) 7.5 (4.2–11.6) 2618 (19) 49.9 (42.8–56.9) 2480 (17) 14.9 (10.2–20.3)
PCR 3
{ 292 (5) 57.7 (39.7–74.6) 294 (5) 16.6 (4.7–33.7) 420 (6) 62.4 (51.9–72.4) 420 (6) 16.9 (11.7–22.9)
By tissue source
Exfoliated cells 1330 (26) 44.7 (38.4–51.1) 1251 (24) 6.5 (4.3–9.2) 914 (16) 58.4 (52.3–64.4) 914 (16) 12.2 (8.4–16.5)
Fixed biopsies 805 (13) 43.4 (31.4–55.7) 586 (12) 13.2 (6.3–22.3) 2352 (30) 52.4 (46.2–58.6) 2149 (28) 14.6 (10.9–18.8)
Fresh biopsies 266 (7) 50.5 (36.1–64.7) 266 (7) 9.1 (4.5–15.2) 1592 (9) 50.7 (42.3–59) 1411 (8) 8.8 (6.3–11.8)
Combined 32 (1) 78.1 (60–90.7) - - 605 (5) 46.5 (25.6–68) 488 (4) 16.3 (10.2–23.3)
*Southern blot, Dot blot, FISH and In Situ Hybridization.
**Polymerase Chain Reaction MY09/11 or Consensus primers.
{Polymerase Chain Reaction SPF, GP5/6, E6, E7 and others.
{Polymerase Chain Reaction MY and GP performed together.
doi:10.1371/journal.pone.0025493.t003
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doi:10.1371/journal.pone.0025493.g005
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than those in previous meta-analyses [11],[14], which estimated
48% for the region. Our prevalence HPV 16/18 rate is similar to
Europe (57.6%) and North America (55.1%), according to the
study published by Smith et al. [14]
Data on ICC has greatly enriched previous reports; we
increased the number of Latin American cases included from
3,010 considered by the last published meta-analysis [14] to 5,542
in our study. Regarding ICC cases, 53.2% harbored HPV 16 and
13.2% HPV18, confirming that they are the first- and second-most
prevalent types, respectively, which agrees with data previously
obtained on other continents and worldwide. The next five-most
common types, (HPV 31, 58, 33, 45, and 52) added 22.6% of
cases. The proportions of cases attributable to HPV16/18 in this
study were similar to previous meta-analyses [10,11,14], which
estimated nearly 65% for the region. Our findings corroborate
that in LA&C the HPV16/18 prevalence of ICC is similar to that
of Asia (66.9%) and lower than that of Africa (70%), Europe
(73.8%) and North America (76.4%), according Smith et al. [14]
Some intra-regional variations of the most common HPV types
have been observed, although these apparent differences may
happen simply by random fluctuation and/or a lack of sample
representativeness of certain countries. For ICC, Mexico, Central
America and the Caribbean showed a slightly lower HPV16/18
prevalence than South America (64.2% vs. 67.3% respectively).
Particularly, Argentina shows the highest prevalence rate for
HPV16/18 in both HSIL (65.4%) and ICC (77.1%). It is
interesting to point out that the 12 Argentine studies incorporated
samples from women of different provinces of the country,
including aboriginal communities (Quechua [37] and Guarani
[39] populations), revealing similar HPV16/18 prevalence data.
In 11.6% of HSIL and 7.5% of ICC, HPV detection resulted
positive, but the viral type could not be identified (‘‘other type’’);
these cases most likely represent the failed detection of known
types (almost certainly different than HPV 16 and 18) rather than
infections of yet-undiscovered types.
In this review, multiple-type HPV infections were detected in
16.8% of HSIL and 12.6% of ICC, although the frequency of
multiple infections depends largely on the number of HPV types
tested for within a given study. The attribution of ICC etiology to
HPV types is increasingly complicated by the rising prevalence of
multiple co-existing types. It was suggested that infections with
multiple HPV types seem to act synergistically in cervical
carcinogenesis [109], and it was also associated with poor response
and with reduced survival in cervical cancer patients. [110].
However, other study indicates that despite the presence of many
viruses infecting the same anatomical site, only one genotype
would be responsible for the disease [111].
HPV18 and 16 had the highest ICC:HSIL prevalence ratio
in our studies, as found in Smith et al. meta-analysis [14].
Figure 7. Distribution HPV 16/18 in HSIL in LA&C.
doi:10.1371/journal.pone.0025493.g007
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prevalent in HSIL than in ICC. These lowest ratios were observed
for many different types and lower than reported [14].
As more data is accumulated, it is supportive to observe that
HPV16/18 accounts for two-thirds of ICC in LA&C. The
proportion of ICC cases potentially averted by the current
approved vaccines may be even higher than the aforementioned
one if cross-protection against non-vaccine high-risk HPV types
(like HPV31 and 45) is found to be clinically effective in reducing
the incidence of ICC and HSIL caused by these genotypes. The
information given by this work would be also useful in LA&C for
the evaluation of polyvalent vaccines (currently in development)
for the prevention of ICC associated to more than eight or nine
high-risk HPV types.
Limitations of our meta-analysis include the cross-sectional
design of the included studies and their inherent risk of bias, lack of
representativeness, the HPV type-specific prevalence variation and
HPV type-specific sensitivity of different PCR protocols [112].
There is evidence of considerable heterogeneity between studies.
Heterogeneity could not be ruled out even by the pre-designed
subgroup analysis: by country, region, and GNI World Bank
classification. However inconsistencies might be explained by
variations in the population and methods utilized. To address this
issue we chose the random effect model meta-analysis to combine
data in order to obtain conservative (wider) confidence intervals,
which may result more informative than central estimates. In
addition 61% of the patients included in the meta-analysis came
from only three countries (Argentina, Brazil and Mexico) and one
should be cautious when extrapolating our summary results to the
entire region. Further, many studies did not type for a broad range
of HPV types, and cyto-histological diagnoses across studies were
not standardized. The poor infrastructure of research in molecular
biology in many countries highlights the need to consider strategic
alliances and promoting regional research consortia on the topic of
HPV. In this way, according to the World Health Organization
HPV Laboratory Network (WHO HPV LabNet) guidelines, the
establishment of a Regional HPV LabNet would be extremely
useful [113]. This is initiative would support the laboratory
standardization and quality assurance of HPV typing methods to
promote international comparability of results, promoting an
appropriate vaccine introduction and virological surveillance in
the vaccine era.
Although information on the histological type of ICC was
collected, its discrimination was not always clear and the data
came mostly from SCC. For this reason we presented only global
data of ICC.
This study is the broadest summary of HPV type distribution in
HSIL and ICC in LA&C to date, and it has included the majority
of American countries which have the highest cervical cancer
burdens in the region and worldwide. The presented information
may be of importance for local decision makers to consider the
cervical cancer prevention as a whole, taking into account the
Figure 8. Distribution HPV 16/18 in ICC in LA&C.
doi:10.1371/journal.pone.0025493.g008
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PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e25493relevance of vaccination and updating screening strategies using
type-specific high-risk HPV-DNA-based tests. This work comes
available at the time some Latin American and Caribbean
countries are evaluating the HPV vaccine introduction in their
National Vaccination Schedules, in the frame of the Pan American
Health Organization purchase using revolving fund, which makes
vaccines affordable. Continued surveillance of HPV types in HSIL
and ICC as HPV vaccines are introduced would be useful, to
assess the potential for changing type-specific HPV prevalence in
the post-vaccination era in Latin America.
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